Actively Recruiting
Evaluating the Safety of Skipping Radiotherapy in Young Women With Low-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery
Led by Fudan University · Updated on 2026-08-13
234
Participants Needed
1
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate whether skipping postoperative radiotherapy is safe and acceptable for young women under 40 years old who have low-risk ductal carcinoma in situ DCIS after breast-conserving surgery. This phase II clinical study focuses on patients with low- or intermediate-grade DCIS, tumors 1 cm or smaller, clear surgical margins of at least 3 mm, no comedo necrosis, and a single tumor detected by screening. The goal is to see if avoiding radiotherapy affects the rate of cancer returning in the same breast within five years. Participants will undergo close observation after surgery without receiving radiotherapy. Endocrine therapy may be given based on the doctors recommendation and patient preference. The study follows patients over time with regular clinical check-ups and imaging tests to monitor their condition. The main focus is on the rate of ipsilateral breast tumor recurrence over five years, with additional outcomes including other recurrences, survival rates, quality of life, anxiety, and patient-reported outcomes. Throughout the study, women will have regular clinical and imaging follow-up visits to monitor their breast health closely. Researchers will review results from these exams along with questionnaires assessing quality of life and anxiety levels. The study involves careful tracking of cancer recurrence, survival, and other health events over a five-year period. Participants will be observed for up to 11 years, with the primary outcome measured at five years after surgery.
CONDITIONS
Brief Title
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving Surgery
Research Team
X
Xiaoli Yu
J
Jin Meng
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here